Allied Health & Imaging · Independent exam preparation
VA-BC™ Vascular Access Decision Guide Study Guide
Practise device selection, vein preservation, safe insertion, maintenance and complication decisions for VA-BC, with 60 concepts, original questions and recall cards.
By CertMedbry · Updated 1 November 2026
Choose appropriate access, preserve vessels, protect asepsis and distinguish complications that require different interventions. These 60 selected concepts develop clinical reasoning across all eight VA-BC domains. The complete VACC Approved Test Specification defines the full examination scope, including specialized devices and techniques beyond this selective guide.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification does this guide address?
The Vascular Access Certification Corporation awards the Vascular Access-Board Certified™ credential, abbreviated VA-BC™. VACC describes the examination as measuring basic knowledge, skills and abilities expected of professionals working in vascular access. The workbook label Vascular Access Certification (VA-BC) refers to this examination. It does not identify a separate RN, nurse practitioner or imaging-modality examination.
How many questions are scored, and how much time is available?
VACC states that the examination contains 150 questions, with 125 used to compute the score and 25 unscored questions. Examination time is 2.5 hours. A separate 15-minute tutorial precedes the examination, and a separate 15-minute survey follows it.
What question styles and delivery environments are verified?
The verified format is four-option multiple choice at recall, application and analysis levels. VACC offers Prometric test centers and ProProctor remote proctoring. The supplied issuer descriptions do not establish computer adaptivity. The 20 questions here are independent single-best-answer drills and do not predict a passing result.
Which blueprint applies, and how should conflicting handbook summaries be interpreted?
The current outline is based on the 2025 Job Analysis. Its eight weights are Device Assessment and Selection 14%; Patient Assessment 18%; Preparation 11%; Insertion 11%; Care and Maintenance 14%; Troubleshooting Complications and Interventions 16%; Professional Development and Evidence-Based Practice 8%; and Legal and Ethical Considerations 8%. The standalone specification allocates 125 scored items across these domains. The 2026 handbook's detailed specification agrees, although an abbreviated summary omits the legal domain. Its 2020 analysis/June 2021 reference is historical. No separate implementation date is stated for the 2025 specification.
VACC — Detailed Content Outline · Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification · VACC Certification and Recertification Candidate Handbook — 2026 · VACC VA-BC Job Analysis Report — June 2025
What language, jurisdiction and source dates matter?
VACC states that the examination is available only in English and that examination references reflect United States clinical practice. The 2026 candidate handbook expires December 31, 2026. Clinical guidance has separate dates: the CDC catheter guideline originated in 2011 with later updates, the cited SHEA prevention update is from 2022, and the ultrasound position statement is from 2019. Australian clinical references support identified principles here; FDA reporting duties are specifically United States requirements.
VACC — About the Exam · VACC Certification and Recertification Candidate Handbook — 2026 · CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections · SHEA/IDSA/APIC — Strategies to Prevent Central Line-Associated Bloodstream Infections: 2022 Update · Society of Hospital Medicine — Recommendations on Ultrasound Guidance for Vascular Access
Does this guide cover the complete official outline?
No. Its 60 concepts selectively develop common decisions across every domain. The full outline additionally includes dialysis, apheresis and aquapheresis devices; intraosseous devices; arterial and pulmonary artery catheters; insertion techniques; navigation technologies; and further complications, interventions and professional responsibilities. Use the complete specification to identify remaining study needs.
Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification
This independent preparation guide addresses VACC's Vascular Access Board Certified examination for professionals working in vascular access. Its questions are original learning exercises; certification does not expand a clinician's licensed scope of practice.
Outline used: Current official outline based on the 2025 Job Analysis, Appendix K: Approved Test Specification; corroborated by VACC's current Detailed Content Outline and 2026 Candidate Handbook, which expires December 31, 2026. A separate implementation date is not stated in the outline. The workbook label 'Vascular Access Certification (VA-BC)' maps to this examination; the assigned slug is retained.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Device Assessment and Selection14%
1.When does a short peripheral catheter fit the treatment plan?
A short peripheral catheter provides access through a small peripheral vein and is appropriate when the prescribed therapy is compatible with peripheral administration and the expected course is brief. Selection requires more than finding a visible vein: consider infusate injury potential, treatment frequency, vessel condition and anticipated duration. A therapy that requires central delivery remains unsuitable for a short peripheral catheter even when cannulation is technically easy and the catheter flushes freely.
Apply it
An adult needs brief hydration with a peripherally compatible solution and has suitable forearm veins. Select a short peripheral catheter after assessing the treatment course, rather than choosing central access solely because it might last longer.
Common pitfall: A successful insertion establishes access, not compatibility. Do not infer that every prescribed infusion is safe because blood return and flushing are satisfactory.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections · American Cancer Society — Intravenous Lines and Ports Used in Cancer Treatment
2.Why does a midline remain peripheral access?
A midline terminates in a peripheral upper-arm vein rather than a central vein. Its greater length can support selected courses of peripherally compatible therapy, but length does not provide central dilution or change the infusate's tissue-injury potential. The decisive distinction is the tip location. When the treatment requires central delivery, selecting a midline because it is longer than a short peripheral catheter does not satisfy that requirement or resolve the compatibility problem.
Apply it
A patient is offered a midline for a solution explicitly requiring central administration. Explain that the upper-arm insertion and longer catheter do not meet the central-tip requirement, and request a device plan compatible with the prescribed therapy.
Common pitfall: The term midline describes a peripheral device. Treating it as a smaller PICC can expose peripheral vessels to solutions requiring central administration.
American Cancer Society — Intravenous Lines and Ports Used in Cancer Treatment
3.How can a PICC be inserted peripherally yet provide central access?
Peripherally inserted describes the PICC's entry route; central describes its intended distal tip position. These features answer different questions. An arm entry site does not make a correctly positioned PICC a peripheral-tip device, while an arm catheter with an unconfirmed or displaced tip cannot be assumed to provide appropriate central delivery. Device identification, placement documentation and required tip confirmation must agree before the initial infusion relies on central positioning for safe administration.
Apply it
A newly inserted arm catheter is labeled PICC, but the placement record lacks tip confirmation. Before administering a solution requiring central delivery, obtain the required confirmation rather than relying on the device name or insertion site.
Common pitfall: Neither arm insertion nor the PICC label proves current tip position. Confirm the placement evidence before treating the device as ready for central therapy.
American Cancer Society — Intravenous Lines and Ports Used in Cancer Treatment · Cancer Institute NSW eviQ — Central Venous Access Devices
4.What makes implanted-port access different from an external catheter?
An implanted port has a reservoir beneath the skin connected to an intravascular catheter. Access requires a compatible non-coring needle that reaches and remains appropriately positioned in the reservoir. This differs from attaching directly to the external lumen of a PICC or tunneled catheter. The port's presence alone does not establish readiness: the clinician must identify the device, use suitable access equipment and assess access function before administering the intended therapy.
Apply it
A patient arrives with an implanted chest port and no external tubing. Prepare compatible non-coring access equipment and verify access function; do not approach the device as though an external catheter hub were already available.
Common pitfall: An ordinary needle is not interchangeable with a port-access needle. Device compatibility and correct reservoir access remain necessary even when the skin site appears normal.
American Cancer Society — Intravenous Lines and Ports Used in Cancer Treatment · FDA — C-Port HP Power Injectable Port and Catheter Kits, Premarket Notification
5.How should the number of catheter lumens be chosen?
Choose the fewest lumens essential for the actual treatment plan. Concurrent therapies, incompatibilities and required monitoring may justify additional lumens, but possible future convenience alone does not establish a need. Each lumen adds a connection and a maintenance responsibility, so a larger configuration should have a specific clinical purpose. Reconcile anticipated simultaneous infusions before selection rather than assuming that more lumens automatically provide a safer or more adaptable device for every patient.
Apply it
A patient needs one continuous compatible infusion and no additional simultaneous therapy. A single-lumen device meets the plan; requesting three lumens solely for unspecified future needs adds complexity without an identified treatment requirement in this case.
Common pitfall: Fewest essential does not mean always single-lumen. Several incompatible simultaneous therapies may justify multiple lumens when the clinical plan establishes that requirement clearly.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
6.Why does catheter outer diameter matter during selection?
The catheter's outer diameter determines how much space it occupies within the vein, whereas lumen dimensions relate to delivery performance. Select the smallest outer diameter that still meets therapy requirements, using vessel assessment to judge suitability. A device that is unnecessarily large relative to the vein may compromise the remaining space for venous flow. Conversely, choosing a small device that cannot deliver the prescribed therapy fails the functional requirement despite an attractive size comparison.
Apply it
Two devices can both provide the prescribed therapy, but one has a smaller outer diameter. After confirming suitable vessel dimensions and device performance, favor the smaller appropriate device rather than equating a larger catheter with better access.
Common pitfall: Do not substitute lumen size or gauge assumptions for the actual outer diameter. Vessel occupancy depends on the device dimension entering the vein.
7.Which components must be checked before power injection?
Power injection requires a compatible system, including a rated catheter or port and suitable access components. A power-injectable port does not make an ordinary non-coring needle power rated. Verify the identified device and relevant components against their permitted pressure and flow conditions before connecting the injector. The cited FDA notification illustrates that allowed use depends on the port, catheter and needle combination; its product-specific limits must not be generalized to every implanted port.
Apply it
A port identification card confirms power capability, but the access needle's rating cannot be established. Delay power injection until a compatible rated needle and the remaining system requirements are verified for the planned contrast administration.
Common pitfall: Power capability is not a property of every item attached to a rated port. An unverified component can invalidate the proposed injection setup.
FDA — C-Port HP Power Injectable Port and Catheter Kits, Premarket Notification
8.Why should dialysis access planning influence central-device selection?
Dialysis access planning must account for the patient's future vascular needs as well as the immediate treatment. CDC guidance recommends a fistula or graft rather than a central venous catheter for permanent dialysis access in chronic renal failure. When a catheter is required, site selection must avoid preventable damage to veins needed later. A device that solves today's access problem can still be a poor choice if it jeopardizes future durable dialysis options.
Apply it
A patient beginning chronic dialysis is being considered for indefinite catheter dependence. Recognize that immediate catheter access and permanent dialysis access are different decisions, and include preservation of future fistula or graft options in the treatment discussion.
Common pitfall: Reliable catheter function today does not establish that the catheter is the preferred permanent dialysis solution. Assess the longer access pathway and vascular consequences.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
Patient Assessment18%
9.When should alternatives to intravenous administration be assessed?
Assess whether intravenous administration is needed before exposing the patient to catheter insertion and ongoing device risks. The decision depends on the treatment objective, available routes and whether an alternative can reliably deliver the prescribed therapy. A previous IV order or an anticipated admission does not independently establish current need. If a suitable nonintravenous route meets the treatment goal, avoiding unnecessary access also avoids the insertion attempts and maintenance associated with that access.
Apply it
A clinically stable patient can take and absorb the prescribed oral treatment, and no other IV indication exists. Ask the treating team to reconsider the route before starting repeated cannulation attempts solely to preserve a routine admission practice.
Common pitfall: Route review is a clinical decision, not permission to substitute formulations independently. Confirm that the alternative route meets the prescriber's treatment objectives safely.
10.How should anticipated treatment duration shape access assessment?
Assess the expected course, frequency and setting of therapy before choosing access. Duration helps estimate whether a proposed device can support treatment without avoidable replacements, but it does not override infusate compatibility, vessel preservation or patient circumstances. Include planned treatment after discharge rather than considering only the next infusion. The useful question is whether the device fits the whole foreseeable course, with reassessment when the treatment plan or the patient's condition changes.
Apply it
A patient needs several inpatient doses followed by an extended outpatient course. Assess the complete regimen and maintenance arrangements before device selection, rather than repeatedly replacing short-term access because each day's order is considered separately from the overall plan.
Common pitfall: A duration estimate is one selection factor. It cannot turn a peripherally incompatible formulation into a suitable midline infusion or establish central access by itself.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections · Cancer Institute NSW eviQ — Central Venous Access Devices
11.How does the actual infusate formulation change the peripheral-versus-central access decision?
Evaluate the final formulation: concentration, osmolarity, pH, irritant or vesicant properties, additives, and administration conditions. Hypertonic nutrient solutions can irritate and damage peripheral veins, leading to inflammation and thrombosis. A catheter that flushes easily establishes neither chemical compatibility nor protection against this injury. Formulation-specific labeling can establish a central administration requirement even when another formulation of the same product permits peripheral administration. Device selection must also consider the patient's veins, treatment duration and frequency.
Apply it
Compare two mixed CLINIMIX formulations before additives: 4.25/5 contains 4.25% amino acids and 5% dextrose, with calculated osmolarity 675 mOsm/L; 4.25/10 contains the same amino acid concentration but 10% dextrose, with calculated osmolarity 930 mOsm/L. Which supports peripheral administration? The prescribing information permits peripheral or central administration of 4.25/5 but requires central administration of 4.25/10. Thus, a suitable short peripheral catheter may meet the route requirement for the first formulation, whereas the second requires a CVAD. An existing midline cannot satisfy that central requirement because its tip remains peripheral. These formulation values and restrictions appear in the [CLINIMIX prescribing information, sections 2.2, 3 and 5.6](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dccff103-8695-400c-a15d-cc2fd078760a).
Common pitfall: The CLINIMIX labeling requires central infusion when final osmolarity is at least 900 mOsm/L; this product instruction is not a universal compatibility rule for every medication. A lower osmolarity does not override vesicant properties or other administration restrictions. Reassess the final admixture after additives rather than assuming the original bag's characteristics still apply.
Cancer Institute NSW eviQ — Central Venous Access Devices · American Cancer Society — Intravenous Lines and Ports Used in Cancer Treatment
12.Why is subclavian access concerning in advanced kidney disease?
Subclavian catheterization can lead to subclavian vein stenosis, which may impair venous outflow needed for future dialysis access. CDC therefore advises avoiding the subclavian site in hemodialysis patients and patients with advanced kidney disease. This is a vessel-preservation decision: an infection-prevention preference applicable to some adults does not override a patient's dialysis-related vascular needs. Identify kidney disease and potential future access requirements before settling on the insertion site or device plan.
Apply it
An adult with advanced kidney disease needs central therapy. A clinician proposes subclavian placement because of its infection profile. Raise the stenosis concern and seek a site plan that accounts for future dialysis access and current mechanical risks.
Common pitfall: A site associated with lower infection risk in one population is not universally preferable. Kidney-related vessel preservation can change the appropriate risk balance.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
13.When should difficult-access history prompt ultrasound assistance?
Previous difficult cannulation, limited suitable veins and repeated failures should prompt early skilled assessment rather than automatic repetition of the same approach. Ultrasound can identify vessels that are not readily visible or palpable and support real-time peripheral cannulation. Difficult access alone does not prove that central access is necessary; the prescribed therapy may remain suitable for an ultrasound-guided peripheral device. Match the escalation strategy to both vessel findings and the actual treatment requirements.
Apply it
A patient reports multiple failed landmark attempts during previous admissions and needs peripherally compatible treatment. Arrange assessment by a clinician competent in ultrasound-guided peripheral access before accumulating avoidable attempts or selecting a central catheter solely because access is difficult.
Common pitfall: Escalation should improve the access strategy. Merely changing operators without reviewing anatomy, prior failures and therapy requirements may repeat the same unsuccessful approach.
Society of Hospital Medicine — Recommendations on Ultrasound Guidance for Vascular Access
14.How should a reported dressing or antiseptic allergy be clarified?
Clarify the suspected product, timing, appearance and severity of the previous reaction. Antiseptics, adhesives, securement materials and other components can produce different problems, so a broad statement such as dressing allergy does not identify the responsible exposure. The assessment should distinguish a reaction pattern from mechanical skin damage or possible infection and guide product selection. A documented contraindication to chlorhexidine requires an appropriate alternative rather than ignoring the history because chlorhexidine is commonly preferred.
Apply it
A patient reports an itchy rectangular rash beneath a previous dressing but no systemic symptoms. Identify the products used and inspect the distribution before selecting alternatives; do not automatically record every adhesive and antiseptic as the same allergy.
Common pitfall: A rash near a catheter is not automatically infection or chlorhexidine allergy. Distribution, exposure history and skin findings determine the more plausible explanation.
Cancer Nurses Society of Australia — CVAD Skin Management Algorithm · CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
15.What should a preprocedural ultrasound vessel assessment establish?
Assess vessel identity, anatomy, diameter, depth, patency and relationships to nearby arteries and other structures. For an accessible vein, apply ultrasound compression and observe whether its walls fully come together. Failure to compress fully raises concern for thrombosis and requires further assessment before selecting that vessel. Diameter alone does not establish suitability. Compression has anatomical limits: a segment obscured by the clavicle cannot be directly assessed in the same way. Normal compression of a visible segment does not exclude thrombosis elsewhere along the venous pathway.
Apply it
Before arm access, a large superficial basilic vein remains partly open under compression, while an adjacent vein collapses completely. Avoid selecting the noncompressible vessel pending assessment for thrombosis. Evaluate the compressible alternative's diameter, depth, course and compatibility with the planned catheter and therapy; compressibility alone does not establish overall suitability.
Common pitfall: A dark lumen or apparently adequate diameter does not establish patency. Record the observable compression finding and recognize inaccessible segments. Do not interpret inability to compress a vein hidden behind bone as a positive compression test or claim that a limited normal examination excludes all thrombosis.
Society of Hospital Medicine — Recommendations on Ultrasound Guidance for Vascular Access
16.How does a catheter-to-vein diameter ratio differ from occupied area?
A diameter ratio divides catheter outer diameter by vein internal diameter. With ideal circular cross-sections, the occupied-area fraction is the square of that ratio because area varies with diameter squared. A 2 mm catheter in a 5 mm vein therefore has a 40% diameter ratio but occupies 16% of the modeled cross-sectional area. These calculations describe different quantities. Compare measurements and any stated criterion using the same definition, units and measurement conditions.
Apply it
A colleague calculates 2 divided by 5 and reports that the catheter occupies 40% of the vein's area. Correct the interpretation: the diameter ratio is 40%, while the idealized area fraction is 0.4 squared, or 16%.
Common pitfall: Do not compare an area percentage with a diameter-based criterion. Real veins also deform, so an ideal-circle calculation does not replace clinical vessel assessment.
17.Which home resources must be assessed before discharge with access?
A safe home plan requires more than a functioning catheter and a prescription. Assess the patient's dexterity, understanding and ability to perform required tasks, as well as caregiver availability, supplies, pump training and access to troubleshooting and emergency support. Demonstrated performance is more informative than reassurance alone. If an essential task cannot be performed reliably, arrange additional support or revise the care plan before discharge instead of assuming written instructions will close the gap.
Apply it
A patient understands the infusion schedule but cannot manipulate the required connections because of hand weakness. Confirm whether a trained caregiver or home service can perform those tasks and ensure supplies and contact arrangements are established before discharge.
Common pitfall: Willingness and understanding do not establish physical ability. A patient can explain every step yet still need assistance to carry out the treatment safely.
FDA — Infusion Pumps: Tips for Using Your Pump at Home · Cancer Institute NSW eviQ — Central Venous Access Devices
18.How should communication needs change vascular-access assessment?
Adapt communication to the patient's language, developmental level, cognition and sensory needs so that assessment and decisions reflect meaningful participation. Use appropriate language assistance and plain explanations, then check understanding through the patient's own account. Limited English proficiency or difficulty reading does not establish impaired decision-making capacity. The key distinction is between a communication barrier that can be supported and an inability to understand, appreciate or participate in the particular decision despite appropriate support.
Apply it
A patient gives short answers in English but communicates fluently through a qualified interpreter. Discuss device options with that support and assess understanding directly, rather than assuming the language barrier requires a family member to make the decision.
Common pitfall: Agreement, nodding or a signed form does not demonstrate understanding. Remove communication barriers before interpreting a patient's response as informed acceptance or refusal.
AHRQ — Making Informed Consent an Informed Choice · AHRQ — Tool: Teach-Back
19.How should central insertion-site risks be balanced?
Central-site selection requires weighing infection risk against mechanical complications and patient-specific vascular consequences. A site with a favorable infection profile can still be inappropriate because of anatomy, bleeding concerns, stenosis risk or other clinical factors. CDC explicitly frames site selection as a risk-benefit decision and identifies important exceptions, including advanced kidney disease. The most useful assessment compares realistic options for this patient rather than applying a single site preference without considering its boundaries.
Apply it
Two central sites are technically available, but one creates a significant patient-specific vascular concern. Present the infection and mechanical tradeoffs to the team and select using the full risk profile rather than one infection-prevention ranking.
Common pitfall: Do not treat a population-level site recommendation as an absolute rule. Patient anatomy, dialysis planning and mechanical risks can change the appropriate choice substantially.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
Preparation11%
20.When is hand hygiene required around catheter procedures?
Hand hygiene is required before and after relevant catheter activities, including insertion, access, repair, replacement and dressing care. Gloves provide a barrier during the task but do not replace cleaning the hands at the appropriate moments. Recontamination between preparation and device contact can defeat otherwise correct technique. Organize supplies and the working sequence so that hand hygiene occurs before handling the access system and again after the procedure or removal of contaminated gloves.
Apply it
A clinician prepares supplies, handles a bedside control and then reaches for catheter connections while wearing gloves. Pause to restore appropriate hand hygiene and glove practice before device contact, rather than treating the unchanged gloves as continuing protection.
Common pitfall: Gloves can carry organisms from the environment to a connection. Their presence does not establish that the hands or subsequent working sequence remain clean.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
21.What constitutes maximal sterile barriers for central insertion?
Maximal sterile barriers for central catheter insertion include a cap, mask, sterile gown, sterile gloves and a sterile full-body drape. The barrier set limits contamination from the operator and surrounding patient area during placement. Sterile gloves and a small local drape do not provide the complete protection. CDC applies these precautions to CVC and PICC insertion and guidewire exchange, so an arm insertion site does not exempt a PICC procedure from central-insertion precautions.
Apply it
A PICC tray includes sterile gloves and a small fenestrated drape, but no sterile gown or full-body drape is available. Complete the required barrier setup before insertion rather than treating peripheral entry as a reason to reduce precautions.
Common pitfall: A sterile kit is not proof of a complete barrier setup. Verify each required item and its correct use before the procedure starts.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
22.Why must skin antiseptic dry before catheter insertion?
Skin preparation includes the product's specified application and drying conditions, not simply placing antiseptic on the skin. Allow it to dry according to the manufacturer's instructions before puncture, and maintain asepsis afterward. When chlorhexidine is contraindicated, select an appropriate alternative rather than skipping skin antisepsis. A wet surface is not evidence that the preparation is complete, and touching the prepared site afterward can reintroduce contamination unless aseptic technique is maintained throughout.
Apply it
The planned puncture site remains visibly wet after antiseptic application. Wait for the required drying before insertion and protect the prepared area, rather than puncturing immediately because the operator has already donned sterile gloves and the equipment is ready.
Common pitfall: Do not shorten drying by blotting or assume sterile gloves compensate for incomplete preparation. Product instructions govern the required application and drying conditions.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
23.Which parts require protection during aseptic non-touch technique?
Aseptic non-touch technique protects critical parts and sites that could introduce organisms into the vascular system. Examples include syringe tips, exposed connection surfaces and the prepared insertion site. Protection depends on how the parts are handled, not merely on wearing gloves or using a clean tray. If a critical part contacts a nonsterile surface, restore asepsis by replacing or appropriately reprocessing the affected item before it becomes part of the access pathway.
Apply it
While preparing a flush, a syringe tip touches the outside of a package. Replace the contaminated syringe before connection; continuing because the fluid is sterile would overlook contamination of the surface that joins the vascular access system.
Common pitfall: Clean-looking surfaces are not necessarily suitable for critical-part contact. Asepsis requires preventing contamination at the connection, even when no visible soil is present.
Cancer Institute NSW eviQ — Restoring Patency to a Central Venous Access Device · CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
24.What information makes procedural consent meaningful?
Meaningful consent requires discussion of the proposed procedure, expected benefits, material risks and reasonable alternatives in a form the patient can understand. It also requires an opportunity to ask questions and choose voluntarily. A signature documents part of the process but does not replace the conversation or establish comprehension. Address communication needs and assess understanding before proceeding, especially when the patient expresses uncertainty about why a particular device is being recommended.
Apply it
A patient has signed the form but says, 'I thought this was another ordinary blood draw.' Pause preparation, clarify the proposed catheter and its alternatives, and verify understanding before interpreting the signature as informed permission to proceed.
Common pitfall: A completed form can coexist with misunderstanding. Do not use the signature or a busy schedule as a substitute for an informed discussion.
25.How should a procedure time-out resolve disagreement?
A time-out actively reconciles the patient's identity, intended procedure and planned site with the participating team before the invasive step. Its value comes from detecting and resolving inconsistencies, not from reciting information while work continues. If the order, patient understanding or team plan conflicts, pause and clarify before puncture. A checklist or documented time-out cannot make an unresolved discrepancy safe; the decision must be corrected and shared by those performing the procedure.
Apply it
The team prepares the right arm, but the documented plan specifies the left and the patient reports a prior right-sided problem. Stop the start of insertion and reconcile the intended site and relevant history before proceeding.
Common pitfall: Do not resolve a discrepancy by choosing whichever plan is easiest to execute. The time-out must establish an agreed, clinically justified procedure and site.
Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification
26.Why should comfort and positioning be planned before insertion?
Positioning, anxiety management and pain planning affect whether the patient can tolerate the procedure and maintain the required position. Addressing these needs beforehand supports communication and controlled performance rather than reacting to movement after puncture. Preparation should fit the person's physical limitations and developmental needs while allowing the operator to work safely. If sedation is contemplated, it introduces additional assessment and monitoring responsibilities; it is not a substitute for explanation or appropriate procedural planning.
Apply it
A patient cannot comfortably maintain the proposed arm position because of shoulder pain. Adjust positioning and the comfort plan before sterile preparation, and confirm that the revised setup still allows the clinician to perform the planned insertion safely.
Common pitfall: Do not interpret pain-related movement as simple noncooperation. Reassess comfort, positioning and communication before repeating an attempt under the same unfavorable conditions again.
Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification · Cancer Institute NSW eviQ — Restoring Patency to a Central Venous Access Device
Insertion11%
27.How does dynamic ultrasound differ from a skin mark?
Dynamic ultrasound guides the procedure in real time, allowing the operator to relate advancing equipment to the current vessel position. A preprocedural skin mark records anatomy at one moment and cannot account for movement or changes in probe and patient position. The two approaches therefore provide different safeguards. Preprocedural assessment remains useful, but a mark alone should not replace real-time guidance when performing an ultrasound-guided vascular access procedure requiring ongoing visualization.
Apply it
After a vessel is marked, the patient shifts position before cannulation. Reassess and use real-time guidance during insertion rather than treating the earlier mark as a fixed map of the vessel's present location beneath the skin.
Common pitfall: Using ultrasound before puncture does not automatically make the insertion dynamically guided. The operator must use the live image to guide the procedure.
Society of Hospital Medicine — Recommendations on Ultrasound Guidance for Vascular Access
28.Why is seeing the needle shaft insufficient?
The ultrasound image must establish the needle tip's location, because the tip is the leading point capable of injuring a structure. A visible shaft or bright cross-sectional dot may lie behind the actual tip. If the tip cannot be confidently identified, advancing farther converts uncertainty into risk. Reestablish its location before further advancement. The transferable principle is to control movement using the leading point rather than assuming that any visible needle segment proves safe positioning.
Apply it
A bright needle segment appears near the target vein, but the operator cannot distinguish the tip from the shaft. Stop advancement and adjust visualization to locate the tip before moving farther toward the vessel or nearby structures.
Common pitfall: A convincing image of part of the needle can create false reassurance. Visibility matters only when the operator knows which part is being seen.
Society of Hospital Medicine — Recommendations on Ultrasound Guidance for Vascular Access
29.When must the guidewire be confirmed before dilation?
Before vessel dilation, verify that the needle tip and guidewire are within the intended vein using the appropriate visualization. Dilation enlarges the tract and can magnify the consequences of misplaced access, so earlier impressions of venous entry are insufficient when wire position is uncertain. Blood color, easy wire advancement or an apparently uncomplicated puncture does not replace confirmation. Treat the pre-dilation check as a decision gate that must be satisfied before progressing.
Apply it
A wire advances easily after neck-vein puncture, but its position in the intended vein has not been demonstrated. Pause before dilation and establish intravascular wire location rather than using smooth advancement as permission to enlarge the tract.
Common pitfall: Easy wire passage is not proof of correct placement. Do not let technical momentum carry the procedure past an unresolved pre-dilation safety check.
Society of Hospital Medicine — Recommendations on Ultrasound Guidance for Vascular Access
30.Which ultrasound supplies protect the sterile insertion field?
For a sterile ultrasound-guided vascular procedure, use an appropriate sterile probe sheath and sterile gel while maintaining the planned sterile field. Cleaning the probe is necessary but does not by itself make every exposed surface suitable for contact with that field. The sheath, gel and handling technique work together; a sterile cover does not compensate for contaminated gel or a breach during placement. Check the whole ultrasound setup before the invasive step begins.
Apply it
A disinfected probe is ready with a sterile cover, but only a previously opened nonsterile gel bottle is present. Obtain sterile gel and complete the protected setup before bringing the probe into the sterile procedural field.
Common pitfall: Do not equate disinfection with a sterile barrier. The probe cover, gel and operator handling must all preserve the field during the procedure.
Society of Hospital Medicine — Recommendations on Ultrasound Guidance for Vascular Access
31.What must central-tip confirmation establish before first use?
Central-tip confirmation must establish that the catheter terminates in an acceptable location for the particular device and insertion route, with the result reported and documented before initial use. Confirmation methods vary, but successful cannulation and blood return do not establish distal tip position. For upper-body CVADs, the cited eviQ guidance identifies lower superior vena cava, cavoatrial junction or upper right atrial positions within its recommendations; these locations should not be generalized to every specialized device.
Apply it
A newly inserted PICC has brisk blood return, but no accepted tip-location result is recorded. Withhold initial use until the required confirmation is available and reviewed, especially before therapy that depends on appropriate central tip positioning.
Common pitfall: Patency and tip position are different properties. A catheter can aspirate blood while its distal tip remains malpositioned or insufficiently documented for use.
32.How should an insertion checklist change team behavior?
An insertion checklist creates explicit checkpoints for practices whose omission can cause harm, including asepsis, barriers and appropriate visualization. Its purpose is prospective correction: the team identifies a missing safeguard while it can still be restored. Completing the form after insertion cannot provide that protection. A useful checklist process also allows concerns to be raised and acted upon, so that a documented item reflects performed practice rather than an assumption about what usually happens.
Apply it
An observer notices that part of the sterile barrier setup is missing as the operator prepares to puncture. Use the checklist to pause and correct the omission before insertion instead of documenting the deviation after the device is placed.
Common pitfall: Checklist completion is not equivalent to adherence. A checked box has little preventive value when the associated practice was omitted or the concern went unresolved.
Society of Hospital Medicine — Recommendations on Ultrasound Guidance for Vascular Access · SHEA/IDSA/APIC — Strategies to Prevent Central Line-Associated Bloodstream Infections: 2022 Update
33.When do respiratory symptoms after central insertion require urgent assessment?
New dyspnea, chest discomfort or oxygenation changes after neck or chest central access raise concern for a mechanical complication such as pneumothorax. The temporal relationship makes urgent assessment necessary, but symptoms alone do not establish the diagnosis. Pause the routine procedure or infusion workflow, assess the patient's stability and activate appropriate clinical evaluation. Do not attribute new respiratory findings to anxiety merely because insertion appeared uncomplicated or the catheter provides blood return.
Apply it
Shortly after chest central catheter placement, a patient develops new breathlessness and falling oxygen saturation. Initiate urgent assessment and escalation for a possible mechanical complication rather than proceeding with routine line use while waiting for symptoms to settle.
Common pitfall: Normal catheter function does not exclude an insertion complication outside the lumen. Blood return cannot reassure against pneumothorax or explain a new oxygenation change.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections · Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification
Care and Maintenance14%
34.What findings should routine catheter-site assessment seek?
Assess the site and surrounding area for tenderness, erythema, swelling, leakage and drainage, and relate findings to device function and patient symptoms. An intact dressing does not eliminate the need for assessment. Inspection through a transparent dressing and appropriate palpation can identify concerns; symptoms suggesting infection may require removal of an opaque dressing for examination. Distinguish a normal-looking covering from a clinically normal site, and investigate new findings rather than merely recording dressing integrity.
Apply it
A patient reports new tenderness beneath an opaque dressing, although its edges remain secure. Arrange appropriate direct site assessment instead of documenting the catheter as satisfactory solely because the covering is dry and the infusion pump is running.
Common pitfall: Absence of visible drainage does not exclude a problem beneath an opaque dressing. Patient-reported pain is assessment information that requires an appropriate response.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
35.When should a dressing be changed before its scheduled date?
Replace a catheter dressing promptly when it becomes damp, loose or visibly soiled; the routine calendar does not justify leaving a compromised barrier in place. Choose a dressing suited to current conditions. CDC permits sterile gauze or sterile transparent semipermeable dressings and recommends gauze while a site is bleeding or oozing. Reassess the source of moisture or drainage as well as replacing the covering, because the dressing change alone may not resolve the underlying issue.
Apply it
A central dressing applied yesterday is lifting and wet after bathing. Replace it using the appropriate aseptic process now, assess the site and review moisture protection rather than waiting until the scheduled dressing-change day later in the week.
Common pitfall: Reinforcing a failed covering can conceal moisture or soil without restoring an adequate barrier. Scheduled intervals apply to dressings that remain clinically appropriate.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
36.Which patients fit the CDC chlorhexidine-dressing recommendation?
CDC recommends appropriately FDA-cleared chlorhexidine-impregnated dressings for adults with short-term, non-tunneled central venous catheters. The age and device boundaries matter. Such dressings are not recommended for premature neonates because of serious skin-reaction risk, and the cited update makes no recommendation for other pediatric patients because evidence is insufficient. Separate an affirmative adult recommendation, a premature-neonate restriction and an unresolved pediatric evidence question instead of treating them as one universal instruction.
Apply it
An adult short-term central-line dressing policy is proposed for a premature neonatal unit. Identify the population mismatch and the skin-injury restriction before adoption, rather than extending the adult recommendation solely because infection prevention is the same goal.
Common pitfall: No recommendation is not the same as proven benefit or a universal prohibition. Preserve the distinction between insufficient evidence and a specific safety restriction.
CDC — Updated Recommendations on Chlorhexidine-Impregnated Dressings
37.How should needleless connectors be prepared before access?
Disinfect the connector's access surface using the appropriate antiseptic, friction and application conditions, then allow it to dry before connection. The connector is a potential entry route into the catheter lumen, so a quick superficial touch is not equivalent to adequate disinfection. Repeat appropriate preparation for subsequent accesses as required rather than assuming the first cleaning protects every later connection. Protect the disinfected surface and the connecting syringe tip from recontamination during the sequence.
Apply it
After blood sampling, a clinician immediately reaches to attach another syringe. Ensure the connector receives the required preparation for that access and that the antiseptic dries, rather than assuming a previous scrub covers every connection in the episode.
Common pitfall: Do not invent one universal scrub time for every product and connector. Apply the relevant validated instructions while preserving friction, coverage, drying and asepsis.
Cancer Institute NSW eviQ — Central Venous Access Devices · CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
38.Why must flushing and locking match the device system?
Flushing clears blood and residual infusate from the catheter pathway; locking leaves the prescribed solution within the lumen between uses. The completion sequence helps limit blood reflux into the catheter. A negative-displacement connector can draw fluid backward during syringe disconnection: the cited eviQ sequence places clamping before completion of flushing and before disconnection. A positive-displacement connector expels fluid toward the catheter during disconnection: complete flushing, disconnect, then clamp so that displacement can occur. Verify the actual catheter and connector instructions, including the required solution, volume and sequence.
Apply it
A unit replaces positive-displacement connectors with negative-displacement connectors. Its former routine was to finish flushing, disconnect and then clamp. Continuing that routine can allow disconnection-related reflux before the clamp closes. After verifying the new product instructions, teach staff to clamp before completing the flush and disconnecting, as specified for the negative-displacement example.
Common pitfall: Connector appearance does not establish its displacement mechanism. Clamping too early with a positive-displacement connector can prevent its intended fluid displacement; clamping too late with a negative-displacement connector can permit reflux. Do not transfer a familiar sequence without checking the actual system, and never force a flush against unexplained resistance.
Cancer Institute NSW eviQ — Restoring Patency to a Central Venous Access Device · Cancer Institute NSW eviQ — Central Venous Access Devices
39.How do securement and external-length checks work together?
Securement limits traction and catheter movement, while comparison with the documented external-length baseline helps detect possible migration. These assessments complement rather than replace one another: an apparently secure dressing does not prove unchanged internal position. A new length difference warrants evaluation before relying on the device for therapy that depends on central positioning. Protect the skin and avoid advancing an exposed external segment back through the insertion site as a way to restore the original measurement.
Apply it
A PICC's external segment is longer than the insertion baseline after a traction event. Pause use and arrange assessment of possible migration and tip position rather than retaping the catheter at the old measurement or assuming blood return proves safety.
Common pitfall: External length is a warning cue, not a complete tip-location test. A normal measurement cannot exclude every form of internal malposition or migration.
Cancer Institute NSW eviQ — Central Venous Access Devices · Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification
40.How can teach-back verify catheter-care understanding?
Teach-back asks the patient or caregiver to explain essential information in their own words so the clinician can assess the clarity of the explanation. For practical catheter tasks, demonstration adds evidence of performance. Frame the process as checking the teaching rather than testing the person. If the response reveals a gap, explain differently and check again. Asking only whether the person understands or supplying written instructions does not establish that they can recognize and manage a problem.
Apply it
After teaching dressing protection, ask the caregiver to explain what they would do if it became wet or loose. If they plan to wait several days, reteach the response and check understanding again before completing discharge education.
Common pitfall: Repeating the same explanation more loudly is not a response to misunderstanding. Adapt the teaching and verify the specific action the learner will take.
41.When should an intravascular catheter be removed?
Remove an intravascular catheter promptly when it is no longer clinically essential. Continuing need should be reassessed as treatment changes, including conversion to a suitable nonintravenous route or completion of therapy. A catheter that remains functional still exposes the patient to device-related risks, so function alone is not an indication to retain it. Conversely, removal planning must account for ongoing prescribed therapy rather than treating a change in setting as proof that access is unnecessary.
Apply it
A patient's IV course is complete and the team confirms no remaining access indication. Arrange prompt removal and appropriate site care instead of retaining the functioning catheter for several additional days because obtaining access had originally been difficult.
Common pitfall: Past difficulty obtaining access is not a current treatment indication. Balance foreseeable clinical need explicitly rather than preserving every device indefinitely for possible convenience.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
Troubleshooting Complications and Interventions16%
42.What should new swelling during a peripheral infusion trigger?
New swelling, leakage or discomfort during peripheral infusion suggests that fluid may no longer be entering the vein appropriately. Stop administration and assess the site, device function and infusate before deciding the next steps. The nature of the solution matters: suspected vesicant extravasation requires a specific response that preserves initial access for aspiration. A pump that continues to run does not establish intravascular delivery, and unexplained swelling should not be managed by simply increasing infusion pressure.
Apply it
During a peripheral infusion, the patient notices swelling and tightness despite no pump alarm. Stop the infusion, identify the solution and assess for infiltration or extravasation before deciding device removal and further management for the affected tissue.
Common pitfall: An absent occlusion alarm is not evidence of correct delivery. Tissue can receive infused fluid even while the pump appears to operate normally.
Australian Commission on Safety and Quality in Health Care — Management of Peripheral Intravenous Catheters Clinical Care Standard · Cancer Institute NSW eviQ — Extravasation Management
43.How should suspected vesicant extravasation be managed immediately?
Stop the injection or infusion immediately, seek assistance, leave the access device initially in place and aspirate residual drug through it. Do not flush, because flushing can deliver more vesicant into affected tissue. Subsequent treatment depends on the drug, exposure and assessment findings; antidotes and warm or cold applications are not interchangeable across agents. The immediate principle is to stop further delivery while preserving a route for aspiration and organized drug-specific management.
Apply it
A patient receiving vesicant anticancer therapy reports burning with new local swelling. Stop administration, call for assistance and retain the device for aspiration without flushing, then initiate the identified agent's extravasation pathway and document the assessment.
Common pitfall: Removing access immediately can lose the aspiration route. Applying a generic compress before identifying the agent can also conflict with the appropriate drug-specific treatment.
Cancer Institute NSW eviQ — Extravasation Management Clinical Procedure
44.Which mechanical causes should be assessed before an occlusion drug?
Check for closed clamps, kinked tubing, connection problems and position-related obstruction before assuming the lumen contains a thrombus. A mechanical block prevents flow without requiring a chemical or thrombotic cause, so a clearance medication will not correct a closed clamp. Assess the patient and device systematically and stop if excessive resistance is encountered. If simple external causes do not explain the problem, continue the evaluation rather than escalating syringe pressure or repeatedly attempting forceful flushing.
Apply it
A central infusion stops after the patient's tubing is repositioned. Inspect clamps and the full external pathway first. If a kink explains the interruption, correct it and reassess function before considering pharmacologic clearance for an unproven intraluminal obstruction.
Common pitfall: A prior history of thrombotic occlusion can bias assessment. Each new flow problem still requires review for a current mechanical explanation before drug treatment.
Cancer Institute NSW eviQ — Restoring Patency to a Central Venous Access Device
45.When should chemical precipitation be suspected in an occluded catheter?
A flow problem occurring after incompatible medications or solutions share a lumen should prompt consideration of chemical precipitation. Review the sequence, compatibility and flushing history rather than assuming every occlusion is thrombotic. Treatment must fit the likely material and device; a thrombolytic targets thrombus, not every chemical deposit. Do not force the obstruction through the catheter. Establish the likely cause with appropriate medication review before selecting a specific clearance intervention for that lumen.
Apply it
A previously patent lumen becomes obstructed after sequential administration of solutions later identified as incompatible. Review a possible chemical occlusion with the treating and pharmacy teams rather than automatically repeating a thrombolytic previously used for a different catheter problem.
Common pitfall: Timing suggests a cause but does not prove it. Check mechanical explanations and the actual compatibility history before choosing a chemical clearance strategy.
Cancer Institute NSW eviQ — Restoring Patency to a Central Venous Access Device
46.How does partial occlusion differ from complete occlusion?
Partial occlusion can impair aspiration while still allowing injection; complete occlusion prevents both. This distinction describes function and helps determine the assessment and clearance approach, but it does not by itself prove a thrombotic cause. A catheter that flushes but cannot provide expected blood return still requires evaluation before use. In complete occlusion, forceful injection is inappropriate; the cited eviQ procedure uses a controlled negative-pressure method when prescribed clearance treatment is indicated.
Apply it
A CVAD accepts a gentle flush but repeatedly fails to yield expected blood return. Recognize a possible partial occlusion and assess its cause rather than labeling the catheter fully patent or treating it as a complete blockage.
Common pitfall: Easy injection is not a complete patency assessment. Do not assume that a lumen with impaired aspiration is safe for every intended infusion.
Cancer Institute NSW eviQ — Restoring Patency to a Central Venous Access Device
47.What findings raise concern for catheter-associated venous thrombosis?
New limb or neck swelling in a patient with a vascular catheter warrants evaluation for venous thrombosis, especially when accompanied by pain or altered device function. These findings are concerning but nonspecific, so they do not establish the diagnosis alone. Assess the clinical picture and arrange appropriate diagnostic evaluation rather than treating the symptom as ordinary dressing tightness. Distinguish suspected venous thrombosis outside the catheter from an intraluminal occlusion that primarily affects aspiration or injection.
Apply it
A patient with a PICC develops new unilateral arm swelling extending beyond the dressing area. Escalate for assessment of possible venous thrombosis and other causes rather than simply loosening tape or instilling a lumen-clearance drug as definitive treatment.
Common pitfall: A patent lumen does not exclude thrombosis around the catheter. Conversely, limb swelling alone is insufficient to diagnose thrombosis without appropriate clinical evaluation.
Cancer Institute NSW eviQ — Restoring Patency to a Central Venous Access Device · Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification
48.Why does fever alone not establish a catheter infection?
Fever in a patient with a central catheter may reflect catheter infection, another infection or a noninfectious process. Evaluate the patient, insertion site, alternative sources and appropriate diagnostic findings rather than assigning causation from catheter presence alone. CDC advises against removing a CVC solely because fever occurs, while clinical instability or additional evidence may demand a different response. Also distinguish standardized surveillance definitions from the individualized clinical assessment used to diagnose and manage the patient.
Apply it
A stable patient with a central catheter develops fever and symptoms suggesting another infection source. Assess both the patient and catheter and obtain the indicated evaluation rather than declaring a catheter-source bloodstream infection from fever alone.
Common pitfall: Avoid both extremes: fever does not prove a catheter source, but a normal-looking insertion site does not exclude bloodstream infection or eliminate assessment needs.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections · CDC NHSN — Bloodstream Infection Event, January 2026
49.When is guidewire exchange inappropriate for a suspected infected catheter?
CDC advises against guidewire exchange of a non-tunneled catheter suspected of infection. Reusing the existing access tract can carry forward the contamination problem rather than resolving it. This differs from selected exchange situations involving a malfunctioning catheter without evidence of infection. The distinction requires clinical assessment of the indication for replacement; technical convenience or difficult access does not erase the infection concern when deciding whether the existing tract should be reused.
Apply it
A non-tunneled central catheter is suspected of being infected, and a guidewire exchange is proposed to avoid another puncture. Identify the infection-related restriction and pursue an appropriate replacement plan rather than treating exchange as a universally safer option.
Common pitfall: Do not generalize a malfunction-related exchange option to suspected infection. The reason for replacement determines whether preserving the existing tract is appropriate here.
CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
50.How can dermatitis, mechanical skin injury and infection be distinguished?
Assess the distribution, symptoms, timing and appearance of impaired skin around the catheter. An itchy pattern matching a product's contact area suggests dermatitis; superficial damage associated with adhesive removal suggests mechanical injury. Tenderness, drainage and other local or systemic findings raise concern for infection. These patterns guide the differential rather than establish certainty from one sign. Review product exposure and removal technique while maintaining appropriate site protection and investigating features that could indicate infection.
Apply it
After repeated dressing removal, a patient has superficial skin loss along an adhesive edge without drainage or systemic symptoms. Assess mechanical injury and improve skin protection and removal technique, while checking for additional findings that would alter the differential.
Common pitfall: Do not treat every red area with the same intervention. Infection, contact reactions and adhesive trauma require different reasoning and can sometimes coexist clinically.
Cancer Nurses Society of Australia — CVAD Skin Management Algorithm
Professional Development and Evidence-Based Practice8%
51.How is a CLABSI incidence rate calculated?
Calculate a CLABSI incidence rate by dividing eligible CLABSI events by central-line days and multiplying by 1,000. The denominator represents device exposure, not admissions or total patient days. For example, three events during 1,500 central-line days produce two events per 1,000 central-line days. Apply the relevant surveillance definitions consistently before calculating. A rate comparison is meaningful only when event definitions, surveillance locations and denominator collection are sufficiently comparable across the periods being compared.
Apply it
A unit reports four CLABSIs over 2,000 central-line days. Calculate 4 divided by 2,000 multiplied by 1,000, giving 2 per 1,000 central-line days; do not substitute the unit's admission count or total patient days.
Common pitfall: A lower raw event count can coexist with a higher incidence rate if device exposure falls substantially. Always examine the denominator and surveillance definitions.
52.What does the central-line utilization ratio measure?
The central-line utilization ratio divides central-line days by patient days for the same location and period. It describes how much patient care time involved central-line exposure, rather than the infection risk per exposed day. For example, 300 central-line days during 1,000 patient days yield a ratio of 0.30. Interpret this alongside clinical need and infection measures; a change in utilization can alter exposure even when infection-prevention performance per line-day is unchanged.
Apply it
A unit records 450 central-line days and 900 patient days in one month. Its utilization ratio is 0.50. Compare this exposure measure with clinical necessity reviews rather than calling it an infection rate or multiplying it by 1,000.
Common pitfall: Patient days belong in the utilization denominator, while central-line days belong in the CLABSI incidence denominator. Swapping them answers a different measurement question entirely.
53.How should complete bundle adherence be measured?
For an all-components bundle measure, count an encounter as compliant only when every specified component is performed. High individual-component percentages do not guarantee equally high complete-bundle adherence, because different encounters may miss different elements. Define the eligible encounters and required components before auditing, then report the complete numerator over the eligible denominator. Component-level findings remain useful for locating weaknesses, but they answer a different question from whether the whole preventive package was delivered.
Apply it
Of 50 observed eligible insertions, 44 include every required bundle element. Complete adherence is 88%, even if each individual component exceeds 90%. Use the missing-element data to target improvement without relabeling incomplete encounters as fully compliant.
Common pitfall: Averaging component percentages can conceal fragmented performance. Do not present that average as the proportion of patients who received every required bundle element.
SHEA/IDSA/APIC — Strategies to Prevent Central Line-Associated Bloodstream Infections: 2022 Update
54.What distinguishes a randomized trial from clinician-selected treatment?
Randomization assigns participants to study groups by chance rather than by clinician preference or patient prognosis. This helps create comparable groups and reduces selection bias, although chance imbalances and other study limitations can remain. A comparison of two products is not automatically randomized, and a large sample does not supply random allocation. When appraising a study, identify how assignment actually occurred before accepting the design label or interpreting a treatment difference as evidence of causation.
Apply it
A report compares two catheter products, but clinicians chose the newer product for patients with easier access. Identify the assignment as nonrandomized and consider selection bias rather than accepting a randomized-trial label based on the presence of comparison groups.
Common pitfall: Random sampling and random treatment allocation are different processes. A representative sample does not establish that intervention groups were assigned by chance in the study.
55.How should vascular-access competence be assessed?
Competence requires evidence that a clinician can perform the relevant procedure safely and consistently, including assessment, asepsis, technical execution and recognition of complications. Procedure counts describe exposure but do not establish performance quality. Combine appropriate education and supervised practice with observed assessment against defined criteria. Reassessment can identify skill gaps after changes in equipment or practice. The important distinction is between having performed a procedure many times and demonstrating the required behaviors when evaluated.
Apply it
A clinician has logged many insertions but repeatedly loses needle-tip visualization during assessment. Provide targeted feedback and supervised practice, then reassess the defined skill rather than granting independent practice solely because the numerical experience requirement has been reached.
Common pitfall: Confidence, attendance certificates and high procedure counts are indirect indicators. They cannot replace observation of the specific safety-critical skills required for independent performance.
Society of Hospital Medicine — Recommendations on Ultrasound Guidance for Vascular Access · CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
Legal and Ethical Considerations8%
56.When may a patient withdraw consent for vascular access?
A patient with decision-making capacity may withdraw consent, including after signing a form or after preparation has begun. Pause the proposed intervention, clarify the patient's concerns and discuss the consequences and reasonable alternatives without coercion. Assess and support communication rather than equating disagreement with incapacity. The relevant principle is continuing voluntary authorization: an earlier agreement does not permanently transfer control of the decision to the clinician or make later refusal irrelevant to the care plan.
Apply it
Before puncture, a patient who understands the discussion says they no longer want the proposed catheter. Stop, explore the reason and notify the treating team to discuss options rather than proceeding because the signed form is already in the chart.
Common pitfall: An inconvenient refusal is not evidence of incapacity. Do not substitute family preference or completed paperwork for the capable patient's current voluntary decision.
57.What makes vascular-access documentation clinically useful?
Record the assessment, procedure, number of attempts, relevant device information, interventions, complications and patient response accurately. Useful documentation allows the next clinician to distinguish the insertion baseline from later change and understand why decisions were made. A final statement such as catheter working does not replace the history of difficult attempts or a complication. The record should reflect what actually occurred, including corrective action, rather than presenting an uncomplicated version because the eventual device functioned.
Apply it
A catheter works after two unsuccessful attempts and one successful attempt. Document the actual attempt history, relevant findings and patient response along with final device information, so subsequent clinicians can interpret symptoms and plan future access appropriately.
Common pitfall: Do not erase earlier difficulty by documenting only the successful endpoint. An accurate outcome statement still needs the clinically relevant events that preceded it.
Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification · Cancer Institute NSW eviQ — Central Venous Access Devices
58.How should manufacturer instructions guide product use?
Manufacturer instructions identify a product's intended use, compatible components and operating limitations. Verify the actual model rather than assuming that similar appearance or a shared brand makes two devices interchangeable. A product-specific clearance or rating supports that identified configuration, not every catheter in its class. When selecting a setup, reconcile the proposed use with the relevant instructions before treatment; familiarity with an older device does not establish compatibility or permission for a newly supplied component.
Apply it
A replacement needle resembles the previous power-rated model, but its labeling does not confirm that capability. Verify the exact model's instructions and compatibility before power injection rather than relying on appearance, brand familiarity or another product's clearance document.
Common pitfall: A regulatory document for one product is not a universal device instruction. Do not transfer its pressure, flow or compatibility limits to another model.
FDA — C-Port HP Power Injectable Port and Catheter Kits, Premarket Notification · Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification
59.How does a United States device user facility classify serious injury and determine its reporting duty?
FDA defines serious injury as illness or injury that is life-threatening, causes permanent impairment of a body function or permanent damage to a body structure, or requires medical or surgical intervention to prevent such permanent impairment or damage. Any one criterion qualifies. A user facility must report information reasonably suggesting that a device caused or contributed to serious injury to the manufacturer, or to FDA when the manufacturer is unknown, within 10 work days of awareness. Suspected device-related death requires reports to both FDA and the manufacturer within the same deadline.
Apply it
A hospital patient's catheter fractures, and a fragment embolizes. An interventional radiologist removes the fragment and documents that removal was necessary to prevent permanent vascular damage. The patient recovers without lasting impairment. First classify the event: it meets the serious-injury definition because intervention was needed to prevent permanent damage. Next select the destination: with a known manufacturer, the hospital must report to that manufacturer within 10 work days of becoming aware of the reportable event. Recovery does not remove the reporting obligation, and definitive proof of device causation is unnecessary.
Common pitfall: Hospitalization or treatment alone does not automatically establish this regulatory category; determine whether a stated serious-injury criterion is met. Conversely, successful preventive treatment can make an event reportable even when permanent damage never develops. Provide urgent care and internal escalation immediately. User-facility malfunction reports without reportable death or serious injury are generally voluntary; manufacturer duties differ. An MDR report does not itself prove causation, and MAUDE report counts cannot establish comparative event rates without reliable exposure data.
FDA — Medical Device Reporting: How to Report Medical Device Problems · Mandatory Reporting Requirements: Manufacturers, Importers and Device User Facilities | FDA · About Manufacturer and User Facility Device Experience (MAUDE) Database | FDA · Questions and Answers on the Medical Device Reporting (MDR) Regulation | FDA
60.How does fiscal responsibility support appropriate vascular access?
Fiscal responsibility includes judicious use of supplies, equipment and clinical time, together with accurate recording of charges. Resource stewardship should follow the treatment need and required safety practices; choosing unnecessary equipment or omitting an essential barrier are both poor decisions for different reasons. Distinguish avoidable waste from necessary preparation. Charge documentation should correspond to the service and supplies actually provided rather than an assumed standard package that may not match the patient's care.
Apply it
A routine preference would open several unused device kits before assessing the patient. Complete the assessment and gather the appropriate equipment deliberately, while preserving required sterile supplies and recording charges accurately for the care and materials actually provided.
Common pitfall: Cost reduction does not justify skipping asepsis or selecting an unsuitable device. Stewardship means avoiding unnecessary consumption while still meeting the patient's clinical requirements.
Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the 14/18/11/11/14/16/8/8 blueprint to organize study, with particular attention to patient assessment and complication reasoning.
- Separate insertion site, tip location, peripheral compatibility and device capability; these describe different properties.
- Preserve future vascular options by connecting kidney history, vein dimensions, catheter diameter and site-specific risks.
- Practise the pre-dilation guidewire check, needle-tip tracking, full sterile barriers and documented central-tip confirmation.
- Distinguish infiltration, vesicant extravasation, mechanical obstruction, chemical precipitation, thrombotic occlusion and venous thrombosis.
- Keep CLABSI incidence, device utilization and complete-bundle adherence denominators separate.
- Review the complete official outline for specialized devices, insertion methods, arterial monitoring, catheter removal and complications beyond these selected concepts.
A practical preparation plan
1. Map the complete blueprint
Read the approved 2025 specification and mark each topic as secure, uncertain or unfamiliar. Include Legal and Ethical Considerations at 8%, despite its omission from the handbook's abbreviated summary.
2. Build device-selection comparisons
For short peripheral catheters, midlines, PICCs, ports and specialized access, compare intended purpose, tip location, therapy compatibility, maintenance demands and vessel-preservation implications.
3. Rehearse insertion decision gates
Explain what must be established before puncture, advancement, dilation and first use. Practise identifying the missing safeguard in a case rather than memorizing equipment names alone.
4. Sort complications by discriminating cues
Create brief cases using swelling, burning, failed aspiration, failed injection, recent incompatible medications, fever and skin-distribution patterns. State the immediate action and what the finding does and does not establish.
5. Calculate and interpret quality measures
Work CLABSI rates per 1,000 central-line days, utilization ratios and complete-bundle adherence. Label each denominator and explain how changes in exposure affect interpretation.
6. Use questions to repair reasoning gaps
Answer the 20 drills before reading explanations. For each error, identify the decisive cue and explain why each alternative is weaker, then revisit the related concept and use flashcards for spaced recall.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- VACC — About the Exam
- VACC — Detailed Content Outline
- Vascular Access Board Certified Examination — 2025 Job Analysis, Approved Test Specification
- VACC Certification and Recertification Candidate Handbook — 2026
- VACC VA-BC Job Analysis Report — June 2025
- CDC — Summary of Recommendations for Prevention of Intravascular Catheter-Related Infections
- CDC — Strategies for Prevention of Catheter-Related Infections
- CDC — Updated Recommendations on Chlorhexidine-Impregnated Dressings
- SHEA/IDSA/APIC — Strategies to Prevent Central Line-Associated Bloodstream Infections: 2022 Update
- Society of Hospital Medicine — Recommendations on Ultrasound Guidance for Vascular Access
- Australian Commission on Safety and Quality in Health Care — Management of Peripheral Intravenous Catheters Clinical Care Standard
- American Cancer Society — Intravenous Lines and Ports Used in Cancer Treatment
- Cancer Institute NSW eviQ — Central Venous Access Devices
- Cancer Institute NSW eviQ — Restoring Patency to a Central Venous Access Device
- Cancer Institute NSW eviQ — Extravasation Management
- Cancer Institute NSW eviQ — Extravasation Management Clinical Procedure
- Cancer Nurses Society of Australia — CVAD Skin Management Algorithm
- AHRQ — Tool: Teach-Back
- AHRQ — Making Informed Consent an Informed Choice
- CDC NHSN — Bloodstream Infection Event, January 2026
- National Cancer Institute — Randomized Clinical Trial
- FDA — Medical Device Reporting: How to Report Medical Device Problems
- FDA — Infusion Pumps: Tips for Using Your Pump at Home
- FDA — C-Port HP Power Injectable Port and Catheter Kits, Premarket Notification
- ID-3995-CVADs-patency-algorithm-V4-March-2024-5.pdf.aspx
- Mandatory Reporting Requirements: Manufacturers, Importers and Device User Facilities | FDA
- About Manufacturer and User Facility Device Experience (MAUDE) Database | FDA
- Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update - PMC
- Questions and Answers on the Medical Device Reporting (MDR) Regulation | FDA
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.